featured
Neoadjuvant Cisplatin and Fluorouracil vs Epirubicin, Cisplatin, and Capecitabine Followed by Resection in Patients With Esophageal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Cisplatin and Fluorouracil Versus Epirubicin, Cisplatin, and Capecitabine Followed by Resection in Patients With Oesophageal Adenocarcinoma (UK MRC OE05): An Open-Label, Randomised Phase 3 Trial
Lancet Oncol 2017 Aug 04;[EPub Ahead of Print], D Alderson, D Cunningham, M Nankivell, JM Blazeby, SM Griffin, A Crellin, HI Grabsch, R Langer, S Pritchard, A Okines, R Krysztopik, F Coxon, J Thompson, S Falk, C Robb, S Stenning, RE LangleyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.